The combination of this MCL1 inhibitor and anti-PD-1 therapy in these mouse models showed enhanced inhibition of melanoma growth and improved CD8+ T cell activation compared to treatment with single agent MCL1 inhibitor or anti-PD-1. The gene discussed is CD8A; the disease is melanoma.